You just read:

Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

News provided by

Bayer HealthCare Pharmaceuticals Inc.

23 Oct, 2012, 16:33 ET